These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22023258)

  • 1. Insight into the biomarkers as the novel anti-psoriatic drug discovery tool: a contemporary viewpoint.
    Rahman M; Zaki Ahmad M; Kazmi I; Akhter S; Beg S; Gupta G; Afzal M; Saleem S; Ahmad I; Adil Shaharyar M; Jalees Ahmed F; Anwar F
    Curr Drug Discov Technol; 2012 Mar; 9(1):48-62. PubMed ID: 22023258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative clinical transcriptomics analyses for new therapeutic intervention strategies: a psoriasis case study.
    Qu XA; Freudenberg JM; Sanseau P; Rajpal DK
    Drug Discov Today; 2014 Sep; 19(9):1364-71. PubMed ID: 24662034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bio-markers as tools for discovery of new psoriasis therapies.
    Braddock M
    Curr Drug Discov Technol; 2012 Mar; 9(1):1. PubMed ID: 22375918
    [No Abstract]   [Full Text] [Related]  

  • 4. Advances in psoriasis physiopathology and treatments: Up to date of mechanistic insights and perspectives of novel therapies based on innovative skin drug delivery systems (ISDDS).
    Sala M; Elaissari A; Fessi H
    J Control Release; 2016 Oct; 239():182-202. PubMed ID: 27381248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of biomarkers as a tool for novel psoriatic disease drug discovery.
    Aggarwal D; Arumalla N; Jethwa H; Abraham S
    Expert Opin Drug Discov; 2018 Sep; 13(9):875-887. PubMed ID: 30124339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging landscape in psoriasis management: From topical application to targeting biomolecules.
    Rapalli VK; Singhvi G; Dubey SK; Gupta G; Chellappan DK; Dua K
    Biomed Pharmacother; 2018 Oct; 106():707-713. PubMed ID: 29990862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Murine models of psoriasis and their usefulness for drug discovery.
    Chuang SY; Lin CH; Sung CT; Fang JY
    Expert Opin Drug Discov; 2018 Jun; 13(6):551-562. PubMed ID: 29663834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psoriasis clinical implications and treatment: a review.
    Raut AS; Prabhu RH; Patravale VB
    Crit Rev Ther Drug Carrier Syst; 2013; 30(3):183-216. PubMed ID: 23614646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dithranol: An Insight into its Novel Delivery Cargos for Psoriasis Management.
    Kadian V; Kumar S; Saini K; Kakkar V; Rao R
    Curr Drug Res Rev; 2020; 12(2):82-96. PubMed ID: 32484107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of developing TNF-α targeted therapy for the treatment of psoriasis.
    Campa M; Ryan C; Menter A
    Expert Opin Investig Drugs; 2015; 24(10):1343-54. PubMed ID: 26289788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psoriasis drug discovery: methods for evaluation of potential drug candidates.
    Svensson L; Røpke MA; Norsgaard H
    Expert Opin Drug Discov; 2012 Jan; 7(1):49-61. PubMed ID: 22468893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and Under Development Treatment Modalities of Psoriasis: A Review.
    Albaghdadi A
    Endocr Metab Immune Disord Drug Targets; 2017; 17(3):189-199. PubMed ID: 28782467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetics in the pathogenesis and pathophysiology of psoriasis vulgaris.
    Trowbridge RM; Pittelkow MR
    J Drugs Dermatol; 2014 Feb; 13(2):111-8. PubMed ID: 24509958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classical to current approach for treatment of psoriasis: a review.
    Rahman M; Alam K; Ahmad MZ; Gupta G; Afzal M; Akhter S; Kazmi I; Jyoti ; Ahmad FJ; Anwar F
    Endocr Metab Immune Disord Drug Targets; 2012 Sep; 12(3):287-302. PubMed ID: 22463723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapies under development for psoriasis treatment.
    García-Pérez ME; Stevanovic T; Poubelle PE
    Curr Opin Pediatr; 2013 Aug; 25(4):480-7. PubMed ID: 23838833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy.
    Rahman M; Akhter S; Ahmad J; Ahmad MZ; Beg S; Ahmad FJ
    Expert Opin Drug Deliv; 2015 Apr; 12(4):635-52. PubMed ID: 25439967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-cytokine therapy in the treatment of psoriasis.
    Kupetsky EA; Mathers AR; Ferris LK
    Cytokine; 2013 Mar; 61(3):704-12. PubMed ID: 23410503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanocarriers Mediated Topical Drug Delivery for Psoriasis Treatment.
    Gungor S; Rezigue M
    Curr Drug Metab; 2017; 18(5):454-468. PubMed ID: 28228078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of tazarotene action in psoriasis.
    Duvic M; Nagpal S; Asano AT; Chandraratna RA
    J Am Acad Dermatol; 1997 Aug; 37(2 Pt 3):S18-24. PubMed ID: 9270552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psoriasis and psoriatic arthritis: separate or one and the same?
    Ciocon DH; Kimball AB
    Br J Dermatol; 2007 Nov; 157(5):850-60. PubMed ID: 17725671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.